Perosphere Technologies has announced the receipt of two prestigious federal grants: a Direct Phase II Small Business Innovation Research grant from the National Heart, Lung, and Blood Institute, part of the National Institutes of Health, and a subaward through an Atlanta Center for Microsystems Engineered Point-of-Care Technologies Center Grant, funded by the National Institute of Biomedical Imaging and Bioengineering.
NHLBI/NIH and ACME POCT/NIH Award Prestigious Grants to Perosphere Technologies to Enhance Novel Broad-Spectrum Point-of-Care Coagulometer
DANBURY, Conn.--(BUSINESS WIRE)-- Perosphere Technologies (Perosphere Technologies Inc.), a private medical technologies company focused on developing coagulation diagnostics, has today announced the receipt of two prestigious federal grants: a Direct Phase II Small Business Innovation Research (SBIR) grant from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), and a subaward through an Atlanta Center for Microsystems Engineered Point-of-Care Technologies (ACME POCT) Center Grant, funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB/NIH). The grants, totaling over $2MM, will fund the further development and commercialization of a novel point-of-care (PoC) coagulometer, known as the Perosphere Technologies POC Coagulometer.
“We are very honored to receive these grants from NIH and ACME POCT, as they will present a unique opportunity to further expand our groundbreaking point-of-care coagulation diagnostics technology,” said Dr. Stefan Zappe, Principal Investigator and Chief Technology Officer at Perosphere Technologies. “Perosphere Technologies aims to revolutionize coagulation testing by providing healthcare professionals with accurate and timely results.”
“The potential applications of the Perosphere Technologies PoC Coagulometer will greatly expand thanks to these grant awards, accelerating our understanding of disease mechanisms and therapeutic approaches,” said Dr. Sasha Bakhru, CEO of Perosphere Technologies. “We are proud of the work and research that have gone into creating this device. By providing physicians with the tools to make faster, better-informed treatment decisions, our technology has strong potential to significantly enhance patient care.”
The device’s portability and versatility make it well-suited for emergency room and emergency vehicle use, as well as for routine care in inpatient and outpatient settings including hospitals, clinics, surgical suites, doctor’s offices, and pharmacies.
About Perosphere Technologies
Perosphere Technologies is changing the way decisions are made for patients at risk for bleeding. A private medical technologies company, Perosphere is focused on development and commercialization of the novel PoC (point-of-care) Coagulometer, which informs diagnosis, treatment, and prevention through precision data, made immediately accessible to all. It is the only point-of-care diagnostic tool that effectively and swiftly tests clotting times across drug classes, including Direct Oral Anticoagulants (DOACs). The fast diagnosis and related appropriate treatment decisions the PoC Coagulometer enables will help establish a new standard of care in hospital emergency departments for patients at risk for bleeding and has the potential to improve efficiency, provide significant cost savings, and better patient outcomes. The PoC Coagulometer has a CE Mark in the EU but is not yet cleared in the US.
For further information, contact us at info@perospheretech.com or +1 (475) 218-4600.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230919499332/en/
Contacts
FOR MORE INFORMATION
Laura O’Neill
FINN Partners
laura.oneill@finnpartners.com
+1 402 499 8203
Source: Perosphere Technologies Inc.
View this news release online at:
http://www.businesswire.com/news/home/20230919499332/en
